Unicycive Therapeutics, Inc. Common Stock (UNCY) Stock Price

UNCYStock

$5.47+27.14%52W

Market Cap$149.84M

P/E—

PEG Ratio—

Div yield—

Beta1.75

UNCY Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-27.42%

Price vs S&P 500 (4W)5.05%

VGM Score45.35

Book Value / Share (Quarterly)$1.49

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.14

Price vs S&P 500 (YTD)-19.41%

Net Profit Margin (TTM)-4159.11%

EPS (TTM)$-2.08

10-Day Avg Trading Volume0.83M

EPS Excl Extra (TTM)$-2.08

EPS (Annual)$-5.48

Dividend / Share (Annual)$0.15

ROI (Annual)-494.27%

Cash / Share (Quarterly)$2.16

ROA (Last FY)-115.98%

EBITD / Share (TTM)$-1.58

Operating Margin (TTM)-2931.41%

Cash Flow / Share (Annual)$-1.42

P/B Ratio3.64x

P/B Ratio (Quarterly)4.40x

Net Income / Employee (Annual)$-1,749,000

Net Interest Coverage (TTM)-1805.00x

ROA (TTM)-82.31%

EPS Incl Extra (Annual)$-5.48

Current Ratio (Annual)2.59x

Quick Ratio (Quarterly)2.06x

3-Month Avg Trading Volume1.24M

52-Week Price Return27.14%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.10

P/S Ratio (Annual)203.32x

Asset Turnover (Annual)0.05x

52-Week High$8.74

EPS Excl Extra (Annual)$-5.48

26-Week Price Return-16.17%

Quick Ratio (Annual)2.18x

13-Week Price Return-30.01%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.40x

Enterprise Value$99.87M

Asset Turnover (TTM)0.05x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-4525.04%

Cash / Share (Annual)$1.87

3-Month Return Std Dev112.91%

Net Income / Employee (TTM)$-1,902,300

ROE (Last FY)-494.27%

Net Interest Coverage (Annual)-9.30x

EPS Basic Excl Extra (Annual)$-5.48

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.08

ROI (TTM)-131.18%

P/S Ratio (TTM)31.15x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$-0.03

Forward P/E2.16x

Price vs S&P 500 (52W)8.83%

Year-to-Date Return-7.45%

5-Day Price Return-5.15%

EPS Normalized (Annual)$-5.48

ROA (5Y Avg)-431.02%

Net Profit Margin (Annual)-4525.04%

Month-to-Date Return6.59%

Cash Flow / Share (TTM)$-1.48

EBITD / Share (Annual)$-4.79

Operating Margin (Annual)-3077.63%

EPS Basic Excl Extra (TTM)$-2.08

P/TBV (Quarterly)6.12x

P/B Ratio (Annual)4.11x

Pretax Margin (TTM)-4159.11%

Book Value / Share (Annual)$1.37

Price vs S&P 500 (13W)-32.81%

Beta1.75x

Revenue / Share (TTM)$0.00

ROE (TTM)-131.18%

52-Week Low$3.71

mGradeC

vgmGradeC

UNCY Earnings Surprise History

Q2 25-0.52est. -0.70

Q3 25-0.33est. -0.53

Q4 25-0.82est. -0.46

Q2 26-0.06est. -0.33

UNCY Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

4.13

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
UNCYUnicycive Therapeutics, Inc. Common Stock	—	—	C	$5.47
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Unicycive Therapeutics, Inc. Common Stock

Unicycive Therapeutics is a biotechnology company developing novel therapies for kidney diseases. Its lead programs include Renazorb, a phosphate-binding agent in development for hyperphosphatemia, and UNI-494, an investigational therapy in late preclinical development for acute kidney injury.